SATSUMA PHARMACEUTICALS, INC. (STSA): Price and Financial Metrics


0.22 (+6.87%)

POWR Rating

Component Grades













Add STSA to Watchlist
Sign Up

Industry: Biotech



in industry

STSA Stock Price Chart Interactive Chart >

Price chart for STSA

STSA Price/Volume Stats

Current price $3.42 52-week high $7.48
Prev. close $3.20 52-week low $2.51
Day low $3.03 Volume 55,200
Day high $3.48 Avg. volume 62,213
50-day MA $3.65 Dividend yield N/A
200-day MA $4.56 Market Cap 107.89M


Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA.

STSA Latest News Stream

Event/Time News Detail
Loading, please wait...

STSA Latest Social Stream

Loading social stream, please wait...

View Full STSA Social Stream

Latest STSA News From Around the Web

Below are the latest news stories about Satsuma Pharmaceuticals Inc that investors may wish to consider to help them evaluate STSA as an investment opportunity.

Satsuma Pharmaceuticals (STSA) Gets a Hold Rating from Leerink Partners

In a report issued on December 17, Marc Goodman from Leerink Partners maintained a Hold rating on Satsuma Pharmaceuticals (STSA – Research Report), with a price target of $5.00. The company's shares closed last Wednesday at $4.65. According to, Goodman is a 2-star analyst with an average return of 0.1% and a 42.5% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Avadel Pharmaceuticals. Currently, the analyst consensus on Satsuma Pharmaceuticals is a Moderate Buy with an average price target of $10.00.

Brian Anderson on TipRanks | December 22, 2021

Short Interest in Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Drops By 17.7%

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) saw a large decline in short interest in November. As of November 30th, there was short interest totalling 373,400 shares, a decline of 17.7% from the November 15th total of 453,900 shares. Currently, 1.7% of the shares of the stock are short sold. Based on an average daily trading volume, of […]

Transcript Daily | December 21, 2021

Goldman Sachs Group Inc. Increases Holdings in Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA)

Goldman Sachs Group Inc. lifted its position in shares of Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) by 27.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,930 shares of the financial services providers stock after acquiring an additional 4,721 shares during the quarter. Goldman [] The post Goldman Sachs Group Inc. Increases Holdings in Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) appeared first on ETF Daily News .

ETF Daily News | December 13, 2021

Millennium Management LLC Acquires 126,853 Shares of Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA)

Millennium Management LLC grew its holdings in shares of Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) by 849.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 141,783 shares of the financial services providers stock after acquiring an additional 126,853 shares during the quarter. []

Dakota Financial News | December 11, 2021

Insider Buying: Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Major Shareholder Buys 2,922 Shares of Stock

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) major shareholder Commodore Capital Lp purchased 2,922 shares of the businesss stock in a transaction dated Wednesday, November 24th. The shares were purchased at an average cost of $5.42 per share, for a total transaction of $15,837.24. The transaction was disclosed in a document filed with the SEC, which can be []

Dakota Financial News | December 1, 2021

Read More 'STSA' Stories Here

STSA Price Returns

1-mo -12.98%
3-mo -18.57%
6-mo -30.06%
1-year -34.48%
3-year N/A
5-year N/A
YTD -24.00%
2021 -2.39%
2020 -76.58%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5002 seconds.